Oxygenta Pharmaceutical (524636) Q2 26/27 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 26/27 earnings summary
10 Nov, 2026Executive summary
Q2 FY26/27 revenue from operations was Rs. 3,349.39 lakh versus Rs. 1,430.23 lakh in Q2 FY25; pre-tax loss narrowed to Rs. 339.54 lakh from Rs. 643.78 lakh.
H1 FY26/27 revenue was Rs. 7,053.44 lakh, with a pre-tax loss of Rs. 590.27 lakh and net loss of Rs. 483.90 lakh.
Financial highlights
Q2 total revenue was Rs. 3,351.41 lakh, including Rs. 2.02 lakh other income; total expenses were Rs. 3,690.96 lakh.
H1 total expenses were Rs. 7,643.71 lakh; finance costs were Rs. 518.92 lakh versus Rs. 157.80 lakh in H1 FY25/26.
Q2 net loss was Rs. 273.53 lakh; H1 net loss was Rs. 483.90 lakh, compared with Rs. 1,103.87 lakh in H1 FY25/26.
Segment performance
Operations comprise a single segment: manufacturing of pharmaceutical products; segmental reporting under Ind AS 108 was not made.
Latest events from Oxygenta Pharmaceutical
- Revenue grew, losses narrowed, and post-fire recovery remained the central challenge.524636
Q4 15/16 - A ₹166.96 lakh loss accompanied a costly revival and a July 2013 production target.524636Q4 12/13
- Working-capital shortages constrained operations as FY17 losses widened to ₹5.81 crore.524636Q4 16/17
- Production resumed, but losses deepened amid heavy revival funding and significant audit and legal risks.524636Q4 13/14
- Fire-driven disruption widened FY15 losses; production resumed, with breakeven targeted for November 2015.524636Q4 14/15
- Plant restoration began after repossession, but legal and financial risks remained substantial.524636Q4 11/12
- Control was restored, but revival followed years of shutdown and extensive equipment damage.524636Q4 10/11
- A Rs 15.55 lakh FY10 loss met a revival plan after management regained the factory.524636Q4 09/10
- Factory shutdowns and disputes drove a Rs 25.34m FY06 net loss.524636Q4 05/06